{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:29:05Z","timestamp":1792182545880,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00228-025-03898-4","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:43:34Z","timestamp":1755729814000},"page":"1569-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management \u2014 current evidence and future outlook"],"prefix":"10.1007","volume":"81","author":[{"given":"Nabiha","family":"Atiquzzaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Razdolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"3898_CR1","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/DMSO.S273147","volume":"13","author":"R Abramczyk","year":"2020","unstructured":"Abramczyk R et al (2020) Diabetes and psoriasis: different sides of the same prism. Diabetes Metab Syndr Obes 13:3571\u20133577","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"3898_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW et al (2021) Psoriasis prevalence in adults in the United States. JAMA Dermatol 157(8):940\u2013946","journal-title":"JAMA Dermatol"},{"key":"3898_CR3","first-page":"143","volume":"14","author":"K Haran","year":"2024","unstructured":"Haran K et al (2024) Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis (Auckl) 14:143\u2013152","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"3898_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J et al (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76(3):377\u2013390","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3898_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ et al (2022) Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol 36(6):797\u2013806","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"3898_CR6","doi-asserted-by":"publisher","first-page":"e0308533","DOI":"10.1371\/journal.pone.0308533","volume":"19","author":"D Karacabeyli","year":"2024","unstructured":"Karacabeyli D et al (2024) Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study. PLoS One 19(8)","journal-title":"PLoS One"},{"issue":"8","key":"3898_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","volume":"127","author":"CF Shaefer Jr.","year":"2015","unstructured":"Shaefer CF Jr., Kushner P, Aguilar R (2015) User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 127(8):818\u2013826","journal-title":"Postgrad Med"},{"key":"3898_CR8","unstructured":"Cerillo JL, Parmar M (2025) Liraglutide. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island"},{"issue":"10","key":"3898_CR9","first-page":"e46623","volume":"15","author":"S Brandfon","year":"2023","unstructured":"Brandfon S et al (2023) Advances in anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus 15(10)","journal-title":"Cureus"},{"key":"3898_CR10","doi-asserted-by":"publisher","first-page":"177953","DOI":"10.1016\/j.ejphar.2025.177953","volume":"1003","author":"S Miranda","year":"2025","unstructured":"Miranda S et al (2025) Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: a systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol 1003","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"3898_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein J et al (2025) The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol 92(4):807\u2013815","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3898_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou A et al (2014) Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 51(1):147\u2013150","journal-title":"Acta Diabetol"},{"key":"3898_CR13","doi-asserted-by":"publisher","DOI":"10.29245\/2767-5157\/2020\/1.1106","author":"S Ramakrishnan","year":"2020","unstructured":"Ramakrishnan S et al (2020) Remarkable improvement in plaque psoriasis with a 4 week short course liraglutide therapy in an obese type 2 DM patient. J Endocrinol Sci. https:\/\/doi.org\/10.29245\/2767-5157\/2020\/1.1106","journal-title":"J Endocrinol Sci"},{"issue":"1","key":"3898_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","volume":"38","author":"M Buysschaert","year":"2012","unstructured":"Buysschaert M, Tennstedt D, Preumont V (2012) Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab 38(1):86\u201388","journal-title":"Diabetes Metab"},{"issue":"11","key":"3898_CR15","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan AE et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54(11):2745\u20132754","journal-title":"Diabetologia"},{"key":"3898_CR16","doi-asserted-by":"publisher","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, Basilico S, Boniardi F, Spagnolo P, Malagoli P, Romanelli P, Secchi F, Iacobellis G (2023) Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep 2023(3):23\u20130017. https:\/\/doi.org\/10.1530\/EDM-23-0017","DOI":"10.1530\/EDM-23-0017"},{"key":"3898_CR17","doi-asserted-by":"crossref","unstructured":"Costanzo G et al (2021) Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep 2021:21-0007","DOI":"10.1530\/EDM-21-0007"},{"issue":"7\u20138","key":"3898_CR18","first-page":"165","volume":"133","author":"J Nowowiejska","year":"2023","unstructured":"Nowowiejska J, Baran A, Flisiak I (2023) The first case of psoriatic skin lesions exacerbation after liraglutide. Pol Arch Intern Med 133(7\u20138):165\u201327","journal-title":"Pol Arch Intern Med"},{"key":"3898_CR19","doi-asserted-by":"crossref","unstructured":"Petkovic-Dabic J et al (2025) Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules 15(1):46","DOI":"10.3390\/biom15010046"},{"issue":"3","key":"3898_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L et al (2022) Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat 33(3):1428\u20131434","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"3898_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A et al (2015) Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2013a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol 29(3):555\u2013559","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3898_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","volume":"161","author":"J Nicolau","year":"2023","unstructured":"Nicolau J et al (2023) Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc) 161(7):293\u2013296","journal-title":"Med Clin (Barc)"},{"key":"3898_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","volume":"150","author":"X Xu","year":"2019","unstructured":"Xu X et al (2019) Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract 150:167\u2013173","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"3898_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern T et al (2013) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol 27(11):1440\u20131443","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3898_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M et al (2014) Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal gammadelta T-cell number: a prospective case-series study. Br J Dermatol 171(1):155\u2013161","journal-title":"Br J Dermatol"},{"key":"3898_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","volume":"107","author":"J Yang","year":"2019","unstructured":"Yang J, Wang Z, Zhang X (2019) GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol 107:124\u2013128","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"3898_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/exd.12081","volume":"22","author":"A Faurschou","year":"2013","unstructured":"Faurschou A et al (2013) Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol 22(2):150\u2013152","journal-title":"Exp Dermatol"},{"issue":"6","key":"3898_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen P, Skov L (2016) Psoriasis and obesity. Dermatology 232(6):633\u2013639","journal-title":"Dermatology"},{"issue":"4","key":"3898_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","volume":"57","author":"AE Hogan","year":"2014","unstructured":"Hogan AE et al (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57(4):781\u2013784","journal-title":"Diabetologia"},{"key":"3898_CR30","doi-asserted-by":"publisher","unstructured":"Mahase E (2024) GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ 386:q1645. https:\/\/doi.org\/10.1136\/bmj.q1645","DOI":"10.1136\/bmj.q1645"},{"issue":"1","key":"3898_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jama.2024.10333","volume":"332","author":"E Harris","year":"2024","unstructured":"Harris E (2024) Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA 332(1):8. https:\/\/doi.org\/10.1001\/jama.2024.10333","journal-title":"JAMA"},{"key":"3898_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020739","author":"LF Laurindo","year":"2022","unstructured":"Laurindo LF et al (2022) GLP-1a: going beyond traditional use. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23020739","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3898_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA et al (2021) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 84(2):432\u2013470","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3898_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029\u20131072","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03898-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:21:47Z","timestamp":1759994507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03898-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3898"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03898-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No consent is needed, as the study did not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No consent is needed, as this manuscript contains no personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"To refine the final written draft of the article, the author(s) utilized artificial intelligence (AI) software, such as Gemini, to assist in identifying and correcting grammatical errors and enhancing the overall readability of the final draft. After using this tool\/service, the author(s) reviewed and edited the content as needed and take (s) full responsibility for the content of the publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement"}}]}}